Ken Griffin Renalytix PLC Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.33 - $1.61 $34,449 - $168,071	104,392 New	104,392 $40,000
Q1 2023 May 15, 2023	BUY	$1.93 - $3.72 $24,354 - $46,942	12,619 New	12,619 $30,000
Q3 2022 Nov 14, 2022	SELL	$1.19 - $2.78 $28,055 - $65,541	-23,576 Reduced 26.9%	64,069 $82,000
Q2 2022 Aug 15, 2022	SELL	$2.45 - $7.81 $21,383 - $68,165	-8,728 Reduced 9.06%	87,645 $215,000
Q1 2022 May 16, 2022	SELL	$5.88 - $15.9 $133,605 - $361,279	-22,722 Reduced 19.08%	96,373 $667,000
Q4 2021 Feb 14, 2022	BUY	$13.43 - $27.4 $1.23 Million - $2.52 Million	91,945 Added 338.66%	119,095 $1.89 Million
Q3 2021 Nov 15, 2021	BUY	$17.91 - $34.78 $127,895 - $248,363	7,141 Added 35.69%	27,150 $544,000
Q2 2021 Aug 16, 2021	BUY	$23.56 - $34.25 $214,490 - $311,812	9,104 Added 83.48%	20,009 $617,000
Q4 2020 Feb 16, 2021	BUY	$10.69 - $16.0 $116,574 - $174,480	10,905 New	10,905 $174,000

3.72M

Ticker RNLX
Exchange OTC
Sector Healthcare
Industry Health Information Services
Shares Outstandng 37,445,900
Market Cap $7.86M
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.